Wantstats
Company ProfilePremium

Ironwood Pharmaceuticals

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Ironwood Pharmaceuticals - Healthcare showcase

Year Founded & Workforce

1998

730 Employees

Industry

Healthcare

Services

IBS-C
I

Ironwood Pharmaceuticals Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Ironwood Pharmaceuticals Overview

Company Headquarter: Massachusetts, US

Founded: 1998

Workforce: 730 Employees

Company Working: Ironwood Pharmaceuticals is a commercial biotechnology company. The company commercializes two innovative primary care products, namely, linaclotide, the US branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), and lesinurad, for the treatment of hyperuricemia associated with gout. It also has a pipeline of innovative product candidates in areas of significant unmet needs, including uncontrolled gastroesophageal reflux disease, diabetic nephropathy, achalasia, heart failure with preserved ejection fraction, and sickle-cell anemia.

Company Snapshot

$150M

Revenue

730

Employees

1998

Founded

SWOT Analysis

Strengths

  • Products are innovative
  • Skilled workforce

Weaknesses

  • Narrow product portfolio
  • Limited presence

Opportunities

  • Expanding the product portfolio according to the market

Threats

  • Tough competition in the market

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
–Clinical Data AnouncementIronwood Pharmaceuticals and Allergan announced that linaclotide is having a positive impact on patients with IBS-C
–CollaborationIronwood Pharmaceuticals entered into a collaboration with Allergan for the co-promotion of Viberzi in the US.

Product Offering

  • Ironwood Pharmaceuticals
    • IBS-C

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 150 Mn in 2015 to USD 298 Mn in 2017.
Ironwood Pharmaceuticals — By Business Segment
Series (USD Mn)201520162017
Sales150274298
R&D Expenditure109.5139.5148.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →